| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d1966444097863eaf8cc99198286323e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2002-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e196f8523839204995e9bff9efaf3e47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56a682c44cd56ee32e190159c87451e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c53a46a2eb0137feb2ae00a9f7536629
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5029f1ce7f117187dc5c57f12016d8c3 |
| publicationDate |
2002-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2449288-A1 |
| titleOfInvention |
Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders |
| abstract |
Therapeutic formulations comprising an effective amount of IL-2 or other lymphokine and a biodegradable polymeric carrier having reverse gelation properties and the methods of use thereof for local or both local and systemic control of proliferative cell disorders are disclosed. The formulation can be administered intratumorally/peritumorally and forms an IL-2 containing depot. The IL-2-containing depot provides for continuous, prolonged release of IL-2 sufficient to stimulate the production of cytotoxic T lymphocytes which function both locally and systemically, without causing unacceptable side effects. |
| priorityDate |
2001-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |